These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 39055715)

  • 1. Differential tumor immune microenvironment coupled with tumor progression or tumor eradication in HPV-antigen expressing squamous cell carcinoma (SCC) models.
    Shivarudrappa AH; John J; Vashisht M; Ge H; Liu S; Chen J; Siddoway K; Dong R; Chen Z; Wang JH
    Front Immunol; 2024; 15():1405318. PubMed ID: 39055715
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunomodulation to enhance the efficacy of an HPV therapeutic vaccine.
    Smalley Rumfield C; Pellom ST; Morillon Ii YM; Schlom J; Jochems C
    J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32554612
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differences in TCR repertoire and T cell activation underlie the divergent outcomes of antitumor immune responses in tumor-eradicating versus tumor-progressing hosts.
    Woolaver RA; Wang X; Krinsky AL; Waschke BC; Chen SMY; Popolizio V; Nicklawsky AG; Gao D; Chen Z; Jimeno A; Wang XJ; Wang JH
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33414263
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Type I conventional dendritic cells and CD8
    Kirchner J; Plesca I; Rothe R; Resag A; Löck S; Benešová I; Rupp L; Linge A; Wehner R; Krause M; Schmitz M
    Front Immunol; 2024; 15():1414298. PubMed ID: 38938577
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD8
    Masterson L; Lechner M; Loewenbein S; Mohammed H; Davies-Husband C; Fenton T; Sudhoff H; Jani P; Goon P; Sterling J
    Eur J Cancer; 2016 Nov; 67():141-151. PubMed ID: 27669501
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An Immunocompetent Mouse Model of HPV16(+) Head and Neck Squamous Cell Carcinoma.
    Carper MB; Troutman S; Wagner BL; Byrd KM; Selitsky SR; Parag-Sharma K; Henry EC; Li W; Parker JS; Montgomery SA; Cleveland JL; Williams SE; Kissil JL; Hayes DN; Amelio AL
    Cell Rep; 2019 Nov; 29(6):1660-1674.e7. PubMed ID: 31693903
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of DNA Vaccine Targeting E6 and E7 Proteins of Human Papillomavirus 16 (HPV16) and HPV18 for Immunotherapy in Combination with Recombinant Vaccinia Boost and PD-1 Antibody.
    Peng S; Ferrall L; Gaillard S; Wang C; Chi WY; Huang CH; Roden RBS; Wu TC; Chang YN; Hung CF
    mBio; 2021 Jan; 12(1):. PubMed ID: 33468698
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of a Spontaneous HPV16 E6/E7-Expressing Head and Neck Squamous Cell Carcinoma in HLA-A2 Transgenic Mice.
    Peng S; Xing D; Ferrall L; Tsai YC; Roden RBS; Hung CF; Wu TC
    mBio; 2022 Feb; 13(1):e0325221. PubMed ID: 35089069
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential responses to immune checkpoint inhibitor dictated by pre-existing differential immune profiles in squamous cell carcinomas caused by same initial oncogenic drivers.
    Chen SMY; Popolizio V; Woolaver RA; Ge H; Krinsky AL; John J; Danis E; Ke Y; Kramer Y; Bian L; Nicklawsky AG; Gao D; Liu S; Chen Z; Wang XJ; Wang JH
    J Exp Clin Cancer Res; 2022 Apr; 41(1):123. PubMed ID: 35366939
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radioimmunotherapy of experimental head and neck squamous cell carcinoma (HNSCC) with E6-specific antibody using a novel HPV-16 positive HNSCC cell line.
    Harris M; Wang XG; Jiang Z; Goldberg GL; Casadevall A; Dadachova E
    Head Neck Oncol; 2011 Feb; 3(1):9. PubMed ID: 21314983
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An HPV-E6/E7 immunotherapy plus PD-1 checkpoint inhibition results in tumor regression and reduction in PD-L1 expression.
    Rice AE; Latchman YE; Balint JP; Lee JH; Gabitzsch ES; Jones FR
    Cancer Gene Ther; 2015 Sep; 22(9):454-62. PubMed ID: 26337747
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhancement of Tumor Antigen-specific T-cell Responses by Immune Checkpoint Blockade in Human Papillomavirus-related Head and Neck Squamous Cell Carcinoma.
    Chikamatsu K; Ida S; Masuda K; Horikawa M; Hoshino N; Takahashi H; Tada H; Oyama T; Takeda S; Tomidokoro Y; Motegi M
    Anticancer Res; 2024 Jul; 44(7):2921-2931. PubMed ID: 38925841
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunotherapy Targeting HPV16/18 Generates Potent Immune Responses in HPV-Associated Head and Neck Cancer.
    Aggarwal C; Cohen RB; Morrow MP; Kraynyak KA; Sylvester AJ; Knoblock DM; Bauml JM; Weinstein GS; Lin A; Boyer J; Sakata L; Tan S; Anton A; Dickerson K; Mangrolia D; Vang R; Dallas M; Oyola S; Duff S; Esser M; Kumar R; Weiner D; Csiki I; Bagarazzi ML
    Clin Cancer Res; 2019 Jan; 25(1):110-124. PubMed ID: 30242022
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Functional HPV-specific PD-1
    Eberhardt CS; Kissick HT; Patel MR; Cardenas MA; Prokhnevska N; Obeng RC; Nasti TH; Griffith CC; Im SJ; Wang X; Shin DM; Carrington M; Chen ZG; Sidney J; Sette A; Saba NF; Wieland A; Ahmed R
    Nature; 2021 Sep; 597(7875):279-284. PubMed ID: 34471285
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Innovative DNA vaccine for human papillomavirus (HPV)-associated head and neck cancer.
    Wu A; Zeng Q; Kang TH; Peng S; Roosinovich E; Pai SI; Hung CF
    Gene Ther; 2011 Mar; 18(3):304-12. PubMed ID: 20981112
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting interferon signaling and CTLA-4 enhance the therapeutic efficacy of anti-PD-1 immunotherapy in preclinical model of HPV
    Dorta-Estremera S; Hegde VL; Slay RB; Sun R; Yanamandra AV; Nicholas C; Nookala S; Sierra G; Curran MA; Sastry KJ
    J Immunother Cancer; 2019 Sep; 7(1):252. PubMed ID: 31533840
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Squamous cell carcinomas escape immune surveillance via inducing chronic activation and exhaustion of CD8+ T Cells co-expressing PD-1 and LAG-3 inhibitory receptors.
    Mishra AK; Kadoishi T; Wang X; Driver E; Chen Z; Wang XJ; Wang JH
    Oncotarget; 2016 Dec; 7(49):81341-81356. PubMed ID: 27835902
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhanced Cytotoxic CD8 T Cell Priming Using Dendritic Cell-Expressing Human Papillomavirus-16 E6/E7-p16INK4 Fusion Protein with Sequenced Anti-Programmed Death-1.
    Garcia-Bates TM; Kim E; Concha-Benavente F; Trivedi S; Mailliard RB; Gambotto A; Ferris RL
    J Immunol; 2016 Mar; 196(6):2870-8. PubMed ID: 26851223
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of an mRNA-based therapeutic vaccine mHTV-03E2 for high-risk HPV-related malignancies.
    Wang J; Wang Q; Ma L; Lv K; Han L; Chen Y; Zhou R; Zhou H; Chen H; Wang Y; Zhang T; Yi D; Liu Q; Zhang Y; Li X; Cheng T; Zhang J; Huang C; Dong Y; Zhang W; Cen S
    Mol Ther; 2024 Jul; 32(7):2340-2356. PubMed ID: 38715363
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Liberation of functional p53 by proteasome inhibition in human papilloma virus-positive head and neck squamous cell carcinoma cells promotes apoptosis and cell cycle arrest.
    Li C; Johnson DE
    Cell Cycle; 2013 Mar; 12(6):923-34. PubMed ID: 23421999
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.